Stay updated with breaking news from Cardiac Rate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ablation is a mainstay of AF treatment, but disagreement persists regarding its use as a first-line option. In comparing study outcomes, we will explore how ablation is evolving and the rationale for it becoming first-line therapy for some patients with this debilitating arrhythmia.
Adaptive resynchronization therapy can benefit patients with heart failure, intact atrioventricular conduction, and left bundle branch block, even though the AdaptResponse trial technically failed.
The findings challenge pacing recommendations in HFpEF with chronotropic incompetence and should highlight the disorder's systemic nature, say observers.
A study challenges the dogma of beta-blockers for HF with preserved ejection fraction. For now, the strategy might only be for HFpEF patients already with pacemakers.
Sicker patients in the EAST-AFNET4 trial showed a pronounced survival advantage from early rhythm control, compared with a rate-control-first approach, while those with fewer comorbidities missed out.